Creative Planning boosted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 528.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,512 shares of the company’s stock after buying an additional 2,112 shares during the period. Creative Planning’s holdings in USANA Health Sciences were worth $161,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in USNA. Victory Capital Management Inc. increased its position in USANA Health Sciences by 124.7% in the first quarter. Victory Capital Management Inc. now owns 2,117 shares of the company’s stock worth $122,000 after buying an additional 1,175 shares in the last quarter. Nine Chapters Capital Management LLC bought a new position in USANA Health Sciences during the first quarter worth approximately $207,000. KCG Holdings Inc. bought a new position in USANA Health Sciences during the first quarter worth approximately $248,000. Highbridge Capital Management LLC bought a new position in USANA Health Sciences during the first quarter worth approximately $254,000. Finally, HPM Partners LLC bought a new position in USANA Health Sciences during the first quarter worth approximately $268,000. Institutional investors own 43.90% of the company’s stock.
USANA Health Sciences, Inc. (NYSE:USNA) traded up 1.55% on Friday, hitting $58.95. 54,758 shares of the stock were exchanged. USANA Health Sciences, Inc. has a 52 week low of $52.55 and a 52 week high of $150.00. The company’s 50-day moving average is $61.54 and its 200-day moving average is $60.59. The company has a market cap of $1.47 billion, a PE ratio of 15.31 and a beta of 1.10.
USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $0.98 EPS for the quarter, missing the Zacks’ consensus estimate of $1.06 by $0.08. USANA Health Sciences had a return on equity of 30.12% and a net margin of 9.47%. The business had revenue of $257.10 million for the quarter, compared to analyst estimates of $273.61 million. During the same quarter in the previous year, the business posted $2.07 earnings per share. The company’s revenue was down .5% compared to the same quarter last year. On average, analysts predict that USANA Health Sciences, Inc. will post $3.79 earnings per share for the current year.
USANA Health Sciences announced that its Board of Directors has initiated a stock buyback plan on Tuesday, July 25th that permits the company to buyback $64.60 million in shares. This buyback authorization permits the company to repurchase up to 46% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board of directors believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/08/11/creative-planning-purchases-2112-shares-of-usana-health-sciences-inc-nyseusna.html.
A number of research analysts have recently commented on USNA shares. Pivotal Research reaffirmed a “hold” rating and set a $55.00 price objective (down previously from $75.00) on shares of USANA Health Sciences in a research note on Monday, May 1st. BidaskClub raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Tuesday, June 13th.
In other USANA Health Sciences news, Director Gilbert A. Fuller sold 1,483 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $57.67, for a total transaction of $85,524.61. Following the completion of the sale, the director now directly owns 1,483 shares in the company, valued at approximately $85,524.61. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Myron W. Wentz sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 2nd. The stock was sold at an average price of $64.99, for a total value of $2,599,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 171,334 shares of company stock valued at $10,413,675 over the last 90 days. Corporate insiders own 53.20% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNA).
What are top analysts saying about USANA Health Sciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for USANA Health Sciences Inc. and related companies.